Targeting ICAM1 to Ameliorate Vaso‐Occlusion and Inflammation in Sickle Cell Disease

Parul Gupta,Ravindra Kumar
DOI: https://doi.org/10.1111/ejh.14313
2024-10-02
European Journal Of Haematology
Abstract:Sickle cell disease (SCD) is a hereditary disorder characterized by vaso‐occlusion, inflammation, and tissue damage. Intercellular adhesion molecule 1 (ICAM‐1) plays a crucial role in the pathophysiology of SCD by promoting the adhesion of sickle cells to the endothelium, contributing to vaso‐occlusion and tissue damage. The ICAM‐1 gene encodes a glycoprotein that interacts with lymphocyte function–associated antigen 1 (LFA‐1) and macrophage 1‐antigen (Mac‐1) receptors, perpetuating inflammation, and oxidative stress. The NF‐κB signaling pathway regulates ICAM‐1 expression, which is elevated in patients with SCD, leading to increased endothelial cell activation and damage. Targeting ICAM‐1 and its interactions with sickle cells and the endothelium has emerged as a potential therapeutic strategy for managing SCD. This review highlights the complex interplay between ICAM‐1, sickle cells, and the endothelium, and discusses the potential of ICAM‐1‐targeted therapies for mitigating VOC and improving the quality of life for patients with SCD.
hematology
What problem does this paper attempt to address?